Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Sarcoma 1Lymphoid 1Genitourinary 1

Conditions

Lymphoma, Non-Hodgkin 2Lymphoma 2Glioma 2Wilms Tumor 1Waldenstrom Macroglobulinemia 1Triple Negative Breast Neoplasms 1Sarcoma, Synovial 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Recurrence 1Paraproteinemias 1Osteosarcoma 1Neuroectodermal Tumors, Primitive 1Neuroblastoma 1Neoplasms, Plasma Cell 1Neoplasms, Neuroepithelial 1Neoplasms 1Multiple Myeloma 1Medulloblastoma 1Lymphoproliferative Disorders 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Lymphocytic, Chronic, B-Cell 1Immunoproliferative Disorders 1Hodgkin Disease 1Hematologic Diseases 1Gliosarcoma 1

Interventions

Magnetic Resonance Spectroscopy 22Temozolomide 17Specimen Handling 13X-Rays 9Biopsy 9Radiotherapy 8Radiation 8trametinib 6Phantoms, Imaging 6Nuclear Medicine Department, Hospital 6Bevacizumab 6larotrectinib 4erdafitinib 4dabrafenib 4ulixertinib 3palbociclib 3abemaciclib 3Surgical Procedures, Operative 3Nivolumab 3Cyclophosphamide 3vorasidenib 2tipifarnib 2tazemetostat 2selpercatinib 2olaparib 2mirdametinib 2lutetium Lu 177 dotatate 2ivosidenib 2fluorodopa F 18 2fludarabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Glioma × CLR1404 × 90 days × Clear all
NCT03478462 2026-03-18

CLOVER-2

Cellectar Biosciences, Inc.

Phase 1 Active not recruiting
30 enrolled
CNSGenitourinaryLymphoidSarcoma

Diffuse Intrinsic Pontine Glioma, Ependymoma, Glioblastoma, Glioma, Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial, Neuroectodermal Tumors, Primitive, Neoplasms, Neuroepithelial, Gliosarcoma, Rhabdoid Tumor, Desmoplastic Small Round Cell Tumor

NCT05610891 2026-03-18

Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG

Cellectar Biosciences, Inc.

Phase 1 Active not recruiting
50 enrolled
CNS

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡